Google
×
The GALT Investor Relations site contains information about Galectin Therapeutics Inc. clinical trials in NASH cirrhosis and cancer immunotherapy for ...
Investor Relations. Overview · Press Releases + News · Events & Presentations · Corporate Governance · Management · Board of Directors · Committee Composition.
Retail investors account for 55% of Galectin Therapeutics Inc.'s (NASDAQ:GALT) ownership, while insiders account for 21%. Key Insights Galectin Therapeutics' ...
Missing: relations | Show results with:relations
Investor Presentations. Galectin Therapeutics (GALT) Investor Presentation - Slideshow · SA TranscriptsTue, Nov. 22, 2022. Galectin Therapeutics (GALT) Presents ...
Missing: relations | Show results with:relations
$2.38
Financial analysts and individual investors can rely on the chain to gauge the stock's performance, monitor its activity, and see prices changes when making an ...
The Investor Relations website contains information about Galectin Therapeutics Inc.'s business for stockholders, potential investors, and financial analysts. 2.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports ( ...
... relation to -$0.24 expected by the market ... GALT Earnings History. Report Date ... investors and does not represent returns that any investor actually attained.
Missing: relations | Show results with:relations
In depth view into GALT (Galectin Therapeutics) ... Galectin Therapeutics Inc (GALT). 1.99 -0.02 (-1.00%) USD ... Investor Relations URL, https://investor ...
Investor Relations Intelligence. Featured Solutions. Nasdaq Boardvantage® · Board Evaluations · Nasdaq IR Insight® · Nasdaq Metrio · See All Solutions ->. About.